Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF01741330PMID 1901031PMCID PMC11038474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor

  2005cited by this paper
• Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

  2004cited by this paper
• Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers

  2004cited by this paper
• Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

  1990cited by this paper
• Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

  1989cited by this paper
• Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

  1989cited by this paper
• Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.

  1989cited by this paper
• Chemotherapy of mice bearing syngeneic tumors with 1,3-bis (2-chloroethyl)-1-nitrosourea is effective only in normal, but not in irradiated or nude, mice: role of L3T4+ (CD4+) and Lyt-2+ (CD8+) T cells.

  1988cited by this paper
• Protein kinase C (PKC) inhibitors inhibit primary (1-0) but not secondary (1-1) or cloned cytotoxic T lymphocytes.

  1988cited by this paper
• Requirements for triggering of lysis by cytolytic T lymphocyte clones.

  1987influential reference
• Protein kinase C required for cytotoxic T lymphocyte triggering.

  1987cited by this paper
• Antigen-receptor interaction requirement for conjugate formation and lethal-hit triggering by cytotoxic T lymphocytes can be bypassed by protein kinase C activators and Ca2+ ionophores.

  1987influential reference
• Serine esterase in cytolytic T lymphocytes

  1986cited by this paper
• Phorbol-ester stimulated lysis of weak and nonspecific target cells by cytotoxic T lymphocytes.

  1986cited by this paper
• Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma.

  1985cited by this paper
• Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives.

  1985cited by this paper
• Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

  1983cited by this paper
• Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.

  1982cited by this paper
• Effect of phorbol esters on alloimmune cytolysis.

  1982cited by this paper
• Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.

  1981cited by this paper
• IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

  1980cited by this paper
• Xenogeneic Monoclonal Antibodies to Mouse Lymphoid Differentiation Antigens *

  1979cited by this paper
• The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315-tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells

  1978cited by this paper
• Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.

  1978cited by this paper
• Effectiveness of murine leukemia chemotherapy according to the immune state

  1977cited by this paper
• Host immune potentiation of drug responses to a murine mammary adenocarcinoma

  1976cited by this paper
• Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system

  1976cited by this paper
• Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

  1973cited by this paper
• Modification of tumor regression by immunologic means.

  1969cited by this paper

• Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

  2006cites this paper
• Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.

  2001cites this paper
• Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.

  1996cites this paper
• Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.

  1995cites this paper
• Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome

  1995cites this paper
• Effects of Rehmannia glutinosa polysaccharide b on T-lymphocytes in mice bearing sarcoma 180.

  1995cites this paper
• Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

  1994cites this paper
• Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

  1994cites this paper
• Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

  1994influential citation
• Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor

  1992cites this paper